Control of spasticity caused by multiple sclerosis & spinal cord lesions, & in childn caused by cerebral palsy. Adjunctive management of neurogenic bladder. Management of refractory trigeminal neuralgia.
Adult Initially 5 mg tid. Can be increased gradually every 3 days by 5 mg to max of 80 mg/day in several doses. Childn 2-10 yr 20-60 mg/day, 12-24 mth 10-20 mg/day (from starting dose 0.3-0.75 mg/kg/day up to 2 mg/kg/day). Impaired renal function or those undergoing chronic haemodialysis Approx 5 mg/day.
Not recommended in Parkinson's disease or spasticity arising from strokes, cerebral palsy or rheumatoid disorder. Patients who use their spasticity to maintain posture or to increase function. Monitor clinical state & EEG of patients w/ epilepsy at regular intervals. Concomitant use w/ alcohol & other CNS depressants. May affect ability to drive or operate machinery. Pregnancy. Not recommended during lactation. Elderly.
Occasional hypotensive effect w/ antihypertensives. Additive CNS depressant effect w/ alcohol & other CNS depressants. May produce severe aggravation of hyperkinetic symptoms w/ lithium.
Sign Out
